1. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial. (10th September 2019) Authors: Guo, Y; Ahn, M -J; Chan, A; Wang, C -H; Kang, J -H; Kim, S -B; Bello, M; Arora, R S; Zhang, Q; He, X; Li, P; Dechaphunkul, A; Kumar, V; Kamble, K; Li, W; Kandil, A; Cohen, E E W; Geng, Y; Zografos, E; Tang, P Z Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1831 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗